Opinion
Video
Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer
Author(s):
Panelists discuss optimal durations for PARP inhibitor maintenance therapy in ovarian cancer, exploring how long patients are typically kept on PARPi in both first-line and second-line maintenance settings.
Video content above is prompted by the following:
- Briefly comment on key findings and final OS data from the PRIMA trial, evaluating niraparib 1L maintenance therapy in newly diagnosed advanced ovarian cancer.
- What implications do these findings have and what impact may they have on the treatment paradigm for ovarian cancer?
- What new insights can be drawn about long-term responders to maintenance niraparib from the recent subanalysis of the GEICO-88R study?
Related Videos
Related Content
